KNect365 Life Sciences is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Next Generation Therapeutics

Emerging technologies in antibody engineering and therapeutics

ArticleImage
Monoclonal antibodies are expected to make up just under half of the USD $22.7 billion biologics discovery market by 2025. With this comes great technological innovation and novel approaches to antibody engineering and therapeutics. This whitepaper discusses the latest strategies and challenges, looking at:

- Automation
- Immune repertoire analysis
- Next Generation Sequencing and Bioinformatics
- Display technology and antibody characteristics
- Bispecific Antibodies
- The Challenges of mAbs
- Next generations “antibody-like” protein therapeutics


To download the exclusive whitepaper simply log in or register for a KNect365 account, which will give you access to all our exclusive premium content.

Have any questions about the whitepaper or interested in sponsoring a future whitepaper? Email andrew.burrows@knect365.com.

This piece represents the views of the author and not necessarily the views of KNect365 Life Sciences or the Antibody Therapeutics and Engineering conference series.

Create your KNect365 account

Access this and more industry news, views, and keynotes from influencers and market movers.
Show
Please tick these boxes if you do not wish to receive marketing information relevant to you from KNect365 Life Sciences:
By creating an account you agree to Informa's Terms of Use and Privacy Policy